| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | M B Smith | |
| J Reardon | |||
| E M Olson | |||
| P2860 | cites work | Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 |
| Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 | ||
| Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 | ||
| The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis | Q46242920 | ||
| A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors | Q46616115 | ||
| Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer | Q47943905 | ||
| Maximizing human epidermal growth factor receptor 2 inhibition: a new oncologic paradigm in the era of targeted therapy. | Q54525291 | ||
| Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. | Q54525297 | ||
| Identification of the sites of IgG catabolism in the rat | Q70391543 | ||
| Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab | Q81190157 | ||
| Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer | Q81378656 | ||
| Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | Q27851468 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me | Q30376023 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| The EGF receptor family as targets for cancer therapy | Q34293543 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities | Q34399306 | ||
| Dose scheduling--Herceptin | Q34428758 | ||
| Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer | Q34775370 | ||
| Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer | Q35152539 | ||
| Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial | Q35584284 | ||
| Growth factors and cancer | Q36441643 | ||
| A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours | Q36610615 | ||
| Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors | Q37140621 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| pertuzumab | Q1998021 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 713-722 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Drugs of Today | Q15751956 |
| P1476 | title | Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer | |
| P478 | volume | 48 |
| Q52578959 | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. | cites work | P2860 |
Search more.